Organoid Cell Therapy: South Korea’s First Quality and Non-clinical Guidelines

약사공론（KPA News） South Korea

Overview

The Ministry of Food and Drug Safety (MFDS) of South Korea has issued the world’s first specific guidelines for the quality and non-clinical evaluation of organoid-based cell therapies. These guidelines establish a structured framework for manufacturing and safety assessments to reduce regulatory uncertainty for developers entering clinical trials.

In Depth

Key Findings

South Korea’s Ministry of Food and Drug Safety (MFDS), specifically the National Institute of Food and Drug Safety Evaluation, has published the “Guidelines for Quality and Non-clinical Evaluation of Organoid-based Cell Therapies for Clinical Trials.” Unlike the FDA, EMA, or PMDA, which address these topics within general cell therapy guidelines, this is the first instance globally of a dedicated guideline specifically for organoid-based therapies.

Technical Details

The guidelines apply to advanced biopharmaceuticals using organoids—3D multicellular structures that mimic the biological and functional characteristics of specific organs—derived from autologous or allogeneic starting materials. Key technical requirements include:

• Quality Evaluation: Focuses on Critical Quality Attributes (CQA) such as structural integrity, uniformity of size and shape, cell composition, differentiation/maturation levels, and “organ function recapitulation.” For example, liver organoids are evaluated for metabolic functions, and pancreatic organoids for hormone secretion.
• Risk-based Approach: Emphasizes managing quality throughout the entire process—from starting material selection to maturation—rather than relying solely on final product testing.
• Non-clinical Evaluation: Requires assessment of engraftment, structural recovery of target tissues, and biodistribution. To address species differences, the use of immunodeficient animals, humanized animal models, or New Approach Methodologies (NAMs) is permitted.
• Safety Assessments: Specifically addresses tumorigenicity, including abnormal tissue proliferation and cyst formation, as well as immunogenicity for allogeneic or pluripotent stem cell-derived products.

Background & Context

Organoids are developed from stem cells or tissue-derived cells through self-organization and maturation. While they offer superior physiological relevance compared to 2D models, their complex 3D interactions create variability in quality and biological response. Current clinical trials are in early stages, focusing on organs such as the intestines and pancreas.

Significance & Outlook

The Korea Bio-Pharmaceuticals Association notes that these guidelines provide a roadmap for developers to establish evaluation strategies tailored to their specific product characteristics. While the document is a guidance for applicants and not legally binding, it is expected to accelerate the transition of organoid therapies from the lab to clinical application by clarifying the necessary data for trial approval.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime